Dani Castillo, Medical Oncologist, Researcher, shared on X:
“ACTICCA1: Success in metastatic disease doesn’t guarantee benefit in adjuvant setting.
GemCis failed to win cape after resection of BTC, adjuvant capecitabine as SOC highlighting the need for biomarker/MRD-directed strategies.”
You can also read: ACTICCA-1 at ESMO 2026: Adjuvant Gemcitabine Plus Cisplatin vs Capecitabine in Resected Biliary Tract Cancer
